ema bpc 157 approval status BPC-157 Legal Status: FDA Regulations and Compounding tub-only AOD-9604 LIQUID SPRAY Optimal Electrolyte (Flavor):Berry

ema bpc 157 approval status BPC-157 Legal Status: FDA Regulations and Compounding tub-only AOD-9604 LIQUID SPRAY Optimal Electrolyte (Flavor):Berry

AOD-9604 LIQUID SPRAY

Assuming that the percentage of patients showing an increase in serum vitamin B12 concentration to above 179 pg/ml in both groups is 70%, means the study requires at least 304 patients (152 in each arm) for a threshold of non-inferiority of 10% and a statistical power of 60% with significance set at p  179 pg/ml: patient preference questionnaire Randomisation of patients to treatment group · Visit 1 (start of treatment) Anamnesis: record whether the patient lives alone or with others, lifestyle habits, use of alcohol, whether a vegan diet is followed, whether the patient has undergone gastrectomy Symptoms: record paresthesia, asthenia, loss or reduction of appetite, sadness or change in state of mind, concomitant pharmacological treatment Physical examination: for Hunter’s glositis, positional and vibrational sensitivity Questionnaires: Lobo cognitive mini-exam, EuroQoL-5D Record concomitant treatment Request analyses to be performed one week before next visit: haemogram and serum vitamin B12 Therapeutic plan: patient in oral arm – provision of medication

tub-only

Optimal Electrolyte (Flavor):Berry

Insulin and several GLP-1 medications are obvious examples